RiceBran Technologies has entered into definitive agreements with a group of accredited investors for the purchase of US$6 million of non-convertible original issue discount debentures and US$2 million of convernature made magnesium citrate 250mg softgels 180 cttible preferred stock.###The company intends to use net proceeds from the offering to repay approximately US$4.2 million in debt, including the repayment of all of its outstanding debt with Great Elm Capital (formerly Full Circle Capital). citracal medicine###The remaining proceeds, net of expenses, will be used as working capital to fuel the growth of the company’s rice bran ingredient business in both the food-grade and animal nutrition markets, as well as to begin the implementation of its business realignment to improve overall operating efficiencies.###The US$8calcium carbonate and calcium citrate million offeringnc calcium citrate 1000g includes a combination of debt and equity securities, and would close on February 10, 2017, subject to customary closing conditions. ###The debt component of the offering consists of US$6 million in non-interest bearing non-convertible original issue discount senior secured debt maturing on February 10, 2019 and warrants to purchase 6,875,000 shares of Common Stock at a fixed exercise price of US$0.96 per share. ###The face value of this original issue discount senior secured debt is $6.6 million, reflecting an aggregate original issue discount of US$600,000.###The $4.2 million in debt repayments includes approximately US$4.0 million for the retirement of all of its outstanding debt with Great Elm Capital.###The company also reached an agreement with the holders of approximately US$6.3 million of the company’s current subordinated debt to:###– Extend the maturity of the debt for an additional year to May 10, 2019,###– Reduce the annual interest calcium citrate vitaminsrate from 11.75% to 7% in exchange for new warrants to purchase a total of 3,484,675 shares of Common Stock at an exercise price of US$0.96 per share, ###– The amendment of existing warrants to purchase 289,669 shares to reduce the exercise price from US$5.25 per share to US$0.96 per share, and ###– The payment of approximately US$230,000 in principal and approximately US$270,000 in accrued interest. ###The Offering, debt repayment, and subordinated debt restructuring will result in an annual cash interest savings on the subordinated debt of approximately US$325,000.